Compare NMM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | AGIO |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2007 | 2013 |
| Metric | NMM | AGIO |
|---|---|---|
| Price | $91.53 | $32.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $85.00 | $38.88 |
| AVG Volume (30 Days) | 129.3K | ★ 736.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $5.57 | $76.75 |
| Revenue Next Year | $3.66 | $170.73 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.02 | $22.24 |
| 52 Week High | $95.00 | $46.00 |
| Indicator | NMM | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 44.44 |
| Support Level | $69.21 | $32.43 |
| Resistance Level | $91.96 | $35.88 |
| Average True Range (ATR) | 2.11 | 1.37 |
| MACD | -0.67 | -0.01 |
| Stochastic Oscillator | 53.94 | 33.46 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.